Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PATRES

Financiado

Cerrado

Novel antibiotics against multi drug resistant pathogens

Being among the most significant challenges facing modern medicine, the massive growth of multi-drug resistance prolongs illnesses and increases the risk of early death, thus creating a global clinical threat. The limited arsenal... ver más

30/04/2015

WEIZMANN

164K€

Presupuesto del proyecto: 164K€

Líder del proyecto

WEIZMANN INSTITUTE OF SCIENCE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2015-04-30 No tenemos la información de la convocatoria

0% 92% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

WEIZMANN

0.00€ | Lider

Proyectos interesantes

DIVANTI

Medical Technol...

Biotechnology

100K€ Cerrado

GNA NOW

Medical Technol...

Pharmaceuticals

22M€ Cerrado

NOVRIB

Medical Technol...

Data Science

2M€ Cerrado

PID2020-113521RB-I00

Medical Technol...

Biotechnology

278K€ Cerrado

NAfrAM

Medical Technol...

Biotechnology

190K€ Cerrado

ENABLE

Medical Technol...

Pharmaceutical...

101M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

WEIZMANN INSTITUTE OF SCIENCE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 164K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Being among the most significant challenges facing modern medicine, the massive growth of multi-drug resistance prolongs illnesses and increases the risk of early death, thus creating a global clinical threat. The limited arsenal of available antibiotics dictates an urgent need for novel approaches, as it suffers from (i) resistance to one or several antibiotics and (ii) marginal distinction between the antibiotics sites in bacteria and in patients, causing toxicity or side effects. As resistance-acquiring mechanisms are species-specific and as many antibiotics target ribosomes, we developed novel methodologies for increasing the battery of available potent antibiotics by benefiting from the breakthroughs of our NOVRIB ERC funded project: the unexpected rapid determination of the only available high resolution structure of a ribosome from a genuine pathogen, worldwide. In this PoC project we propose to exploit the unique tools provided by this structure for the commercialization of newly discovered binding sites and contact-networks, for suggesting novel synthetic antibiotics and/or for structure-based alterations of existing ones. Thus, we identified chemical elements associated solely with pathogenic specificity that can provide valuable clues for designing modifications that should increase the potency of the currently known antibiotics; alongside proposing novel binding sites on the ribosome surface. The advantages of our approach are (1) less chance of fast developing resistance, (2) reduced toxicity, (3) potential of decelerating multi-drug antimicrobial resistance development, (4) improved existing ribosomal antibiotics. The significance of our innovating approach stems also from the potential market and the compelling socioeconomic benefits. Hence, we are currently approaching the stage of commercialization and public dissemination.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores